The Evidence Base for the Acellular Dermal Matrix AlloDerm

Jansen, Leigh A.; Caigny, Pascaline De; Guay, Nicolas A.; Lineaweaver, William C.; Shokrollahi, Kayvan

doi:10.1097/sap.0b013e31827a2d23

Cited by 79 publications

(76 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this paper, we also demonstrated the excellent printability of HA-containing bioinks, suggesting that tissue particles from any source do not greatly affect the rheological and printing properties of the bioink. Clinically translated and well established decellularized skin, [ 44,45 ] and placenta/amnion, [ 46 ] have been recently micronized to increase applicability in clinical soft tissue reconstruction as injectables, [ 47 ] (Cymetra, Graftjacket Xpress, AmnioFix) while clinical particles from bone (DMB inject, Allomatrix) and experimental particles from spinal cord, [ 48 ] and small intestinal mucosa [ 49 ] among others, have been explored primarily as injectables for regenerative medicine, but could easily be translated to bioprinting approaches.…”

Section: Discussionmentioning

confidence: 99%

Bioprinting Complex Cartilaginous Structures with Clinically Compliant Biomaterials

Kesti

Eberhardt²,

Pagliccia

et al. 2015

Adv Funct Materials

198

149

View full text Add to dashboard Cite

wileyonlinelibrary.comwith rapid production of patient-specifi c grafts, allowing precise control over internal and external architecture and customized mechanical properties. These techniques can be used for printing biological materials together with living cells, hence the term "bioprinting." 3D bioprinting offers researchers a unique way of depositing cell-laden biocompatible materials, the so-called bioinks, in high-resolution structures with a line thickness on the order of hundreds of microns. Due to the promise of such a technology, several commercial bioprinters have entered the market and bioinks are the subject of intense investigation. [1][2][3] Bioink formulation is often considered one of the most critical aspects of high-resolution cellular bioprinting.Cellular printing requires a bioink with two key properties, namely printability and cytocompatible crosslinking. The identifi cation of printable polymeric systems is mainly done through rheological evaluation of a material's shear thinning behavior and shear recovery. Shear thinning correlates directly with a bioink's ability to be extruded at low pressure (<3 bar), something which ensures high postprinting cell viability. [ 4 ] Shear recovery, on the other hand, relates to the ink's resistance to fl ow after printing, which ensures high fi delity of the printed structure. The presence of cells, however, greatly restricts the crosslinking options as physiologic temperature and pH need to be maintained and harsh chemicals avoided. Hydrogel bioinks can be crosslinked via covalent or physical interactions or a combination thereof. Ultraviolet light initiated crosslinking of (meth)acrylated polymers has been used most often in bioinks, but the presence of potentially toxic monomers and photoinitiators may complicate clinical translation. [5][6][7][8] Physically crosslinked gelation based on temperature, hydrophobic/hydrophilic or ionic interactions has been utilized for precrosslinking of several bioink materials including poly( N -isopropylacrylamide) conjugated hyaluronan (HA-pNIPAAm), [ 9 ] gelatin, [ 10,11 ] alginate, [ 12 ] and gellan. [ 13 ] Precrosslinking before printing or directly during deposition to stabilize the printed lines is generally followed by a fi nal crosslinking which further increases the mechanical properties and stabilizes the whole structure.For cartilage engineering applications, natural polymers from animal or plant sources including alginate, collagen, gelatin, Bioprinting is an emerging technology for the fabrication of patient-specifi c, anatomically complex tissues and organs. A novel bioink for printing cartilage grafts is developed based on two unmodifi ed FDA-compliant polysaccharides, gellan and alginate, combined with the clinical product BioCartilage (cartilage extracellular matrix particles). Cell-friendly physical gelation of the bioink occurs in the presence of cations, which are delivered by co-extrusion of a cation-loaded transient support polymer to stabilize overhanging structures. Rheological properties of...

show abstract

Section: Discussionmentioning

confidence: 99%

Bioprinting Complex Cartilaginous Structures with Clinically Compliant Biomaterials

Kesti

Eberhardt²,

Pagliccia

et al. 2015

Adv Funct Materials

198

149

View full text Add to dashboard Cite

show abstract

“…It has been used in cosmetic surgery, breast reconstruction and dentistry and other surgical reconstructive fields to augment tissue grafts and aid in revascularization. 18 In this study we hypothesized that the cryopreservation of ovarian tissue may preserve fertility. We also hypothesized that the use of the ECTM with robotic surgical assistance may improve outcomes, presumably by aiding the revascularization process.…”

Section: Introductionmentioning

confidence: 99%

First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery

Oktay

Bedoschi

Pacheco

et al. 2016

American Journal of Obstetrics and Gynecology

126

View full text Add to dashboard Cite

Background Ovarian tissue cryopreservation is an experimental fertility preservation method and the transplantation techniques are still evolving. Objective We attempted to improve the technique with the utility of a human decellularized extracellular tissue matrix scaffold, robot-assisted minimally invasive surgery and peri-operative pharmacological support. Study design We prospectively studied 2 subjects with Hemophagocytic Lymphohistiocytosis (P-A) and Non-Hodgkin Lymphoma (P-B) who underwent ovarian tissue cryopreservation at the age of 23, before receiving preconditioning chemotherapy for hematopoietic stem cell transplantation. Both experienced ovarian failure post-chemotherapy and we transplanted ovarian cortical tissues to the contralateral menopausal ovary 7 and 12 years later, using a human extra cellular tissue matrix scaffold and robotic-assistance. The extra cellular tissue matrix scaffold-tissue compatibility was shown in pre-clinical studies. Patients also received estrogen supplementation and baby aspirin preoperatively to aid in the revascularization process. Results Ovarian follicle development was observed approximately ten (P-A) and eight (P-B) weeks after ovarian tissue transplantation. Following eight and seven cycles of in vitro fertilization, nine and ten day-3 embryos were cryopreserved (P-A and P-B, respectively). While the baseline FSH (range: 3.6–15.4 mIU/mL) levels near-normalized by seven months and remained steady post ovarian transplantation in P-A, P-B showed improved but elevated FSH levels throughout (range: 21–31 mIU/mL). Highest follicle yield was achieved 14 (8 follicles; P-A) and 11 months (6 follicles; P-B) post intervention. P-A experienced a chemical pregnancy after the third frozen embryo transfer attempt. She then conceived following her first fresh in vitro fertiliza tion-embryo transfer and the pregnancy is currently ongoing. P-B conceived after the first frozen embryo transfer attempt and delivered a healthy boy at term. Conclusions We reported the first pregnancies after the minimally-invasive transplantation of previously cryopreserved ovarian tissue with an extra-cellular tissue matrix scaffold. This approach seems to be associated with steady ovarian function after a follow up of up to 2 years.

show abstract

“…A production of biovital skin grafts based on human ADMs and in vitro cultured human fibroblasts is a widely discussed issue. However, the vast majority of protocols involve the use of the commercially available cell‐free skin substitute‐ AlloDerm . In this study, because of the widespread availability of allogeneic human skin grafts stored in tissue bank, the research for an optimal, in‐house method of biovital skin substitute production was done.…”

Section: Introductionmentioning

confidence: 99%

Atomic force microscopy in the production of a biovital skin graft based on human acellular dermal matrix produced in‐house and in vitro cultured human fibroblasts

et al. 2017

View full text Add to dashboard Cite

The most efficient method in III° burn treatment is the use of the autologous split thickness skin grafts that were donated from undamaged body area. The main limitation of this method is lack of suitable donor sites. Tissue engineering is a useful tool to solve this problem. The goal of this study was to find the most efficient way of producing biovital skin substitute based on in house produced acellular dermal matrix ADM and in vitro cultured fibroblasts. Sixty samples of sterilized human allogeneic skin (that came from 10 different donors) were used to examine the influence of decellularizing substances on extracellular matrix and clinical usefulness of the test samples of allogeneic human dermis. Six groups of acellular dermal matrix were studied: ADM-1 control group, ADM-2 research group (24 h incubation in 0.05% trypsin/EDTA solution), ADM-3 research group (24 h incubation in 0.025% trypsin/EDTA solution), ADM-4 research group (24 h incubation in 0.05% trypsin/EDTA solution and 4 h incubation in 0,1% SDS), ADM-5 research group (24 h incubation in 0.025% trypsin/EDTA solution and 4 h incubation in 0,1% SDS), and ADM-6 research group (24 h incubation in 0,1% SDS). Obtained ADMs were examined histochemically and by atomic force microscopy (AFM). ADMs were settled by human fibroblasts. The number of cultured cells and their vitality were measured. The obtained results indicated that the optimal method for production of living skin substitutes is colonization of autologous fibroblasts on the scaffold prepared by the incubation of human allogeneic dermis in 0.05% trypsin/EDTA. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 726-733, 2018.

show abstract

The Evidence Base for the Acellular Dermal Matrix AlloDerm

Cited by 79 publications

References 45 publications

Bioprinting Complex Cartilaginous Structures with Clinically Compliant Biomaterials

Bioprinting Complex Cartilaginous Structures with Clinically Compliant Biomaterials

First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery

Atomic force microscopy in the production of a biovital skin graft based on human acellular dermal matrix produced in‐house and in vitro cultured human fibroblasts

Contact Info

Product

Resources

About